5323312025-10-012025-12-315323312025-04-012025-12-315323312025-10-012025-12-31in-capmkt:OtherExpenses1Member5323312025-04-012025-12-31in-capmkt:OtherExpenses1Member5323312025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15323312025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15323312025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532331AJANTPHARMNOTLISTEDINE031B01049AJANTA PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-01-302026-01-12INRCroresQuarterlyThird quarterSingle segmentPharmaceutical2026-01-3013:30:002026-01-3015:00:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated13748400000249700000139981000002350700000535500000-23600000330520000051000000435100000375820000010412100000358600000003586000000868800000-2050000084830000002737700000000027377000002510000027628000002737700000027628000000250700000221.9121.910021.9121.911. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2026. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2025. The review report has been filed with the stock exchange and is available on company website. <BR> 2. The consolidated unaudited financial results of the Company and its wholly owned subsidiaries (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. <BR> 3. Other income / Other expense includes : <BR> <BR> Quarter ended Nine months ended Year ended <BR> Rs. in <BR> Crore 31-Dec-25 30-Sep-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 <BR> Foreign exchange gain (in other <BR> income) 8.55 39.63 17.59 52.80 26.21 28.21 <BR> Foreign exchange <BR> loss (in other <BR> expense) 0 40.95 0 61.34 13.88 8.82 <BR> 4. During nine month ended 31 December 2025, 23,525 (previous year 25,325) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs. 47,050 (previous year Rs. 50,650) and securities premium by Rs. 3.50 crores (previous year Rs. 3.84 crores). Under the same plan, 4,300 Cash Settled Stock Appreciation Rights (SARs) are being vested and will be settled in cash. Hence, there will not be any change in the paid-up share capital and securities premium of the company on account of SARs. <BR> 5. In August 2025, the Income Tax Authorities carried out search operations at certain premises of the Parent Company. The Parent Company has not yet received any formal communication from the Income Tax Authorities in this regard and hence no adjustments have been made in the consolidated financial results for the quarter and period ended 31 December 2025. <BR> 6. The Government of India has announced four Labour Code and have made them effective from 21st November, 2025. The corresponding all supporting rules under these codes are yet to be notified. The parent company is in the process of evaluating the full impact of these new labour codes announced. The parent company has estimated and accounted for incremental liability for own employees and the Company continues to monitor the finalisation of Central/State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. <BR> 7. The Group operates exclusively in one operating segment i.e., "Pharmaceuticals and related products". <BR> 8. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com. <BR> 2025-04-012025-12-31UnauditedConsolidated4031220000011064000004141860000065975000001584400000607600000950430000013750000012777000001140420000031113200000103054000000103054000002386800000256000002412400000078930000000000789300000010970000080027000007893000000080027000000250700000263.1863.170063.1863.17Other expenses3758200000Other expenses11404200000Items that will not be reclassified subsequently to profit or loss28000002800000Items that will not be reclassified subsequently to profit or loss-39900000-39900000900000-14000000Items that will be reclassified subsequently to profit or loss2320000023200000Items that will be reclassified subsequently to profit or loss1356000001356000000025100000109700000UnauditedtrueB S R & Co. LLPtrue2025-07-31